Skip to main content

Table 2 Estimated mean costs and health outcomes averted by RSV interventions (in thousands)

From: Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

RSV-associated (‘000) mean [95% credible interval]No interventionmAb (6 months protection)Maternal vaccine (5 months protection)
Under 1 year1–4 yearsUnder 1 yearUnder 1 year
RSV cases (non-hospital + hospital cases)7649 [5366–10,138]13,192 [10,691–15,486]5928 [4363–7503]6464 [4712–8231]
Hospital admissions668 [142–1853]1150 [258–3139]517 [112–1421]564 [122–1555]
Deaths18 [3–55]22 [4–68]13 [2–40]15 [3–44]
Discounted YLDs16 [10–24]26 [19–36]12 [8–18]13 [9–19]
Discounted YLLs517 [89–1561]593 [103–1832]383 [68–1139]421 [74–1257]
Discounted DALYs532 [102–1581]619 [124–1865]395 [77–1155]434 [85–1276]
Intervention costs (including delivery)NANA430,531 [430,531–430,531]220,775 [220,775–220,775]
Discounted outpatient costs157,114 [69,436–341,707]256,189 [121,141–545,592]122,214 [55,209–264,714]133,078 [59,878–288,301]
Discounted hospital costs75,254 [15,043–213,053]122,362 [25,518–343,347]58,975 [12,080–166,009]64,033 [13,123–179,855]
Discounted total costs232,368 [112,538–443,860]378,551 [194,696–696,863]611,720 [521,121–770,475]417,885 [319,308–592,027]
Burden averted
 RSV cases avertedNANA1721 [979–2659]1186 [641–1924]
 Hospital admissions avertedNANA151 [29–443]104 [19–309]
 Deaths avertedNANA5 [1–15]3 [1–11]
 Discounted DALYs avertedNANA137 [23–423]98 [16–308]
 Net discounted costsNANA379,352 [322,875–408,824]185,517 [144,452–206,446]
  1. Estimated mean [95% credible interval] of undiscounted number (in thousands) of RSV cases, hospital admissions, and deaths and discounted costs and health outcomes (in thousands) pre- and post-RSV interventions summed over 72 Gavi countries in 2022